2299: Poolbeg Pharma: POLB 001 Clinical Data Published — What’s Next for This Immunomodulatory Asset? episode artwork

EPISODE · Jan 29, 2026 · 9 MIN

2299: Poolbeg Pharma: POLB 001 Clinical Data Published — What’s Next for This Immunomodulatory Asset?

from The Vox Markets Podcast · host Vox Markets Podcast

Following the publication of a peer-reviewed paper in Frontiers in Immunology detailing results from the POLB 001 LPS challenge trial, we catch up with Poolbeg Pharma’s CEO Jeremy Skillington and COO Liam Tremble.

NOW PLAYING

2299: Poolbeg Pharma: POLB 001 Clinical Data Published — What’s Next for This Immunomodulatory Asset?

0:00 9:22

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Vox Markets Podcast?

This episode is 9 minutes long.

When was this The Vox Markets Podcast episode published?

This episode was published on January 29, 2026.

What is this episode about?

Following the publication of a peer-reviewed paper in Frontiers in Immunology detailing results from the POLB 001 LPS challenge trial, we catch up with Poolbeg Pharma’s CEO Jeremy Skillington and COO Liam Tremble.

Can I download this The Vox Markets Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!